Werewolf Therapeutics (HOWL) Return on Capital Employed (2021 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Return on Capital Employed of 94.08% for Q2 2026, down 791.0% year-over-year from 13.61% in Q2 2025, and up 57.65% on a QoQ basis from 222.14% in Q1 2026.
Werewolf Therapeutics (HOWL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 94.08% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 94.08%, down 791.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 94.08% (down 791.0% YoY), and the FY2025 annual result was 97.84%, down 4361.0% from the prior year.
- Return on Capital Employed rose to 94.08% in Q2 2026, from 222.14% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 24.48% in Q3 2023 and troughed at 222.14% in Q1 2026.
- A 5-year average of 65.84% and a median of 43.01% in 2022 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2023, when Return on Capital Employed soared 1929 bps; it then slumped 15154 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 39.38% in 2022, then soared by 34 bps to 25.92% in 2023, then slumped by 140 bps to 62.21% in 2024, then slumped by 154 bps to 158.16% in 2025, then soared by 41 bps to 94.08% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 94.08% in Q2 2026, 222.14% in Q1 2026, and 158.16% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | -94.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -94.08% |
| Mar 31, 2026 | -222.14% |
| Dec 31, 2025 | -158.16% |
| Sep 30, 2025 | -104.55% |
| Jun 30, 2025 | -86.16% |
| Mar 31, 2025 | -70.60% |
| Dec 31, 2024 | -62.21% |
| Sep 30, 2024 | -49.26% |
| Jun 30, 2024 | -37.83% |
| Mar 31, 2024 | -29.32% |
| Dec 31, 2023 | -25.92% |
| Sep 30, 2023 | -24.48% |
| Jun 30, 2023 | -25.13% |
| Mar 31, 2023 | -33.93% |
| Dec 31, 2022 | -39.38% |
| Sep 30, 2022 | -41.60% |
| Jun 30, 2022 | -44.42% |
| Mar 31, 2022 | -36.05% |
| Dec 31, 2021 | -30.00% |
| Sep 30, 2021 | -22.42% |